193 related articles for article (PubMed ID: 31983927)
1. Inhaled chemotherapy adverse effects: mechanisms and protection methods.
Sardeli C; Zarogoulidis P; Kosmidis C; Amaniti A; Katsaounis A; Giannakidis D; Koulouris C; Hohenforst-Schmidt W; Huang H; Bai C; Michalopoulos N; Tsakiridis K; Romanidis K; Oikonomou P; Mponiou K; Vagionas A; Goganau AM; Kesisoglou I; Sapalidis K
Lung Cancer Manag; 2020 Jan; 8(4):LMT19. PubMed ID: 31983927
[TBL] [Abstract][Full Text] [Related]
2. Targeted versus chrono-targeted chemotherapy for inhaled chemotherapy in non-small cell lung cancer.
Zarogoulidis P; Darwiche K; Kalamaras G; Huang H; Hohenforst-Schmidt W; Zarogoulidis K
Transl Lung Cancer Res; 2013 Feb; 2(1):E17-22. PubMed ID: 25806211
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer.
Belani CP
Semin Oncol; 1999 Feb; 26(1 Suppl 2):44-54. PubMed ID: 10190783
[TBL] [Abstract][Full Text] [Related]
4. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
5. European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer.
Novello S; Le Chevalier T
Semin Oncol; 2001 Aug; 28(4 Suppl 14):3-9. PubMed ID: 11605176
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
[TBL] [Abstract][Full Text] [Related]
7. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
[TBL] [Abstract][Full Text] [Related]
8. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
9. Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer.
Rosell R; Felip E
Semin Oncol; 2001 Aug; 28(4 Suppl 14):37-44. PubMed ID: 11605182
[TBL] [Abstract][Full Text] [Related]
10. First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China.
Chang Q; Zhang Y; Xu J; Zhong R; Qiang H; Zhang B; Han B; Qian J; Chu T
Thorac Cancer; 2019 May; 10(5):1043-1050. PubMed ID: 30900826
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
12. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel and carboplatin as neoadjuvant chemotherapy in operable (stage I and II) and locally advanced (stage IIIA-N2) non-small cell lung cancer.
Splinter TA
Semin Oncol; 1996 Dec; 23(6 Suppl 16):59-61. PubMed ID: 9007124
[TBL] [Abstract][Full Text] [Related]
14. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
16. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer.
Wagstaff AJ; Keam SJ; McCormack PL
BioDrugs; 2009; 23(3):187-96. PubMed ID: 19627170
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter.
Selting K; Waldrep JC; Reinero C; Branson K; Gustafson D; Kim DY; Henry C; Owen N; Madsen R; Dhand R
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):255-68. PubMed ID: 18759657
[TBL] [Abstract][Full Text] [Related]
20. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
Fang Y; Wang L; Xia GH; Shi MQ
Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
